Edwards Lifesciences (EW) Income from Continuing Operations (2009 - 2026)

Edwards Lifesciences has reported Income from Continuing Operations for 18 years, with the latest figure at $241.4 million in Q2 2026.

• On a quarterly basis, Income from Continuing Operations fell 28.13% year-over-year to $241.4 million in Q2 2026; TTM through Jun 2026 was $978.6 million, a 30.43% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 24.36% from the prior year.
• Income from Continuing Operations was $241.4 million for Q2 2026 at Edwards Lifesciences, down from $380.7 million in the prior quarter.
• The five-year high for Income from Continuing Operations was $406.4 million in Q2 2022, with the low at $64.2 million in Q4 2025.
• Average Income from Continuing Operations over 5 years is $314.5 million, with a median of $338.2 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations surged 66.13% in 2023, then slumped 81.39% in 2025.
• Over 5 years, Income from Continuing Operations stood at $200.5 million in 2022, then soared by 66.13% to $333.1 million in 2023, then increased by 3.57% to $345.0 million in 2024, then plunged by 81.39% to $64.2 million in 2025, then surged by 276.01% to $241.4 million in 2026.
• The last three Income from Continuing Operations figures came in at $241.4 million (Q2 2026), $380.7 million (Q1 2026), and $64.2 million (Q4 2025), per Business Quant data.